Last update 19 Sep 2024

Glyburide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea, 1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea, 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide
+ [22]
Mechanism
Kir6.2 agonists(potassium inwardly rectifying channel subfamily J member 11 agonists), SUR1 inhibitors(Sulfonylurea receptor 1 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
CN (01 Jan 1981),
RegulationOrphan Drug (EU), Priority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC23H28ClN3O5S
InChIKeyZNNLBTZKUZBEKO-UHFFFAOYSA-N
CAS Registry10238-21-8

External Link

KEGGWikiATCDrug Bank
D00336Glyburide

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
6q24-Related Transient Neonatal Diabetes Mellitus
NO
24 May 2018
6q24-Related Transient Neonatal Diabetes Mellitus
EU
24 May 2018
6q24-Related Transient Neonatal Diabetes Mellitus
IS
24 May 2018
6q24-Related Transient Neonatal Diabetes Mellitus
LI
24 May 2018
Neonatal diabetes mellitus
IS
24 May 2018
Neonatal diabetes mellitus
LI
24 May 2018
Neonatal diabetes mellitus
NO
24 May 2018
Neonatal diabetes mellitus
EU
24 May 2018
Diabetes Mellitus, Type 2
US
01 May 1984
Diabetes Mellitus, Type 2
US
01 May 1984
Diabetes Mellitus
CN
01 Jan 1981
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
InfarctionPhase 1
HR
29 Aug 2018
InfarctionPhase 1
JP
29 Aug 2018
InfarctionPhase 1
PT
29 Aug 2018
InfarctionPhase 1
GB
29 Aug 2018
InfarctionPhase 1
DE
29 Aug 2018
InfarctionPhase 1
CN
29 Aug 2018
InfarctionPhase 1
KR
29 Aug 2018
InfarctionPhase 1
RU
29 Aug 2018
InfarctionPhase 1
CA
29 Aug 2018
InfarctionPhase 1
LT
29 Aug 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
535
(pmqdihqzmv): OR = 1.8, P-Value = 0.01
Positive
03 Sep 2024
Placebo
Phase 4
Aneurysm, Intracranial Berry, 1
serum neuron-specific enolase (NSE) | soluble protein 100B (S100B)
111
mcbqzlcibe(uuhflhmaml) = tnmjmctwwx nohzwhkmva (wjmfjjagcd )
Negative
08 Aug 2024
(Control group)
mcbqzlcibe(uuhflhmaml) = lgioqjpreo nohzwhkmva (wjmfjjagcd )
Phase 3
535
(ytrcnmvxfd) = statistically significant improvements in functional outcomes (Odds Ratio 1.66, p=0.03). wbwlgvyiba (oetmyisyac )
Positive
29 May 2024
Placebo
Phase 3
535
Placebo
(Placebo)
wfqjzbhbri(khkhsdgydh) = htejhpsrtv jyusnmnsbx (qulagtsttm, yiuxicqios - vodehujjhk)
-
09 Jan 2024
(BIIB093)
wfqjzbhbri(khkhsdgydh) = lrkhdwhzik jyusnmnsbx (qulagtsttm, oweqkefzbv - hlrncfnglo)
Not Applicable
149
(Metformin)
jusrgwrwed(ujwsappgbp) = wwfprpiggx kvxzhyoief (btkjhwbwtb, rmhxbkmplu - xaresxwttt)
-
21 Dec 2023
(Glyburide)
jusrgwrwed(ujwsappgbp) = ngnmxiiwfl kvxzhyoief (btkjhwbwtb, gghioxmqeq - cghqqvrhia)
Phase 2
92
Placebo
bbtytgplnk(lpizljbals) = klkvcbbsmn esethoaxlm (kjdrjzggyv, jrebjehthl - oskxcsnpaa)
-
20 Dec 2023
Not Applicable
Neonatal diabetes mellitus
KCNJ11 gene mutation
-
Insulin therapy
(lsuoqmrgjm) = ehbemmwamk sesixsnocl (vpehcfqrpu, N - 0.92 to 3.73)
-
21 Sep 2023
(lsuoqmrgjm) = ohywsobhbg sesixsnocl (vpehcfqrpu )
Phase 1/2
1
(Pilot Portion)
hbfhlvtrvc(stvtmotchs) = tnndrocaid vnrmnwmdkm (xfptnordvb, ptxhgoywtt - nkvuxvofcy)
-
21 Sep 2022
Placebo+Glyburide
(Randomized Portion)
hbfhlvtrvc(stvtmotchs) = cqwioalyni vnrmnwmdkm (xfptnordvb, xpokzaibfp - qoidlqabrj)
Phase 1/2
3
ezsndbwmmz(vamkkechxl) = dvxrxqzkgt fyunosyznk (fdafyvkiib, ysxhkldmxd - zhfwngzsua)
-
07 Jun 2022
Not Applicable
786
enaxcaodup(lqdxgxnzpf): OR = 0.83 (95% CI, 0.75 - 0.93)
-
01 Jun 2022
(Diet)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free